BridgeBio Pharma, Inc. — Director's Dealing 2020

Dec 2, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-12-01

Reporting Person: HENDERSON MICHAEL THOMAS (Chief Business Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-01	Common Stock	M	10000	$1.05	Acquired	284211	Direct
2020-12-01	Common Stock	S	3028	$51.1214	Disposed	281183	Direct
2020-12-01	Common Stock	S	6972	$51.6937	Disposed	274211	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-01	Stock Option (Right to Buy)	$1.05	M	10000	Disposed	2029-09-24	Common Stock (10000)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020.

F2: Represents the weighted average sale price of the shares sold from $50.41 to $51.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3.

F3: Represents the weighted average sale price of the shares sold from $51.41 to $52.36 per share.